Floatz logo

FLUOROURACILUM

Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer

Taiho Oncology, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer cohort.

Asset / SponsorPhaseRating
Calcium folinate pentahydrate
Taiho Oncology, Inc.
Phase 2CCC
Pembrolizumab
Taiho Oncology, Inc.
Phase 2CCC
Epirubicin
Taiho Oncology, Inc.
Phase 2CCC
Eloxatin
Taiho Oncology, Inc.
Phase 2CCC
Irinotecan
Taiho Oncology, Inc.
Phase 2CCC

View all 9 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →